Sang Cheul Oh

Title: Sang Cheul Oh: Innovator in Cancer Research

Introduction

Sang Cheul Oh is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer research, particularly through his innovative work on the SMO protein. His research focuses on understanding the molecular mechanisms that influence cancer cell behavior and patient survival rates.

Latest Patents

Sang Cheul Oh holds a patent for an invention titled "Epitope specific to SMO protein, antibody recognizing same, and composition comprising same." This patent identifies the influence of the TGFβ/Smad3/SMO molecular mechanism in cancer cells. It elucidates that a high expression level of SMO is associated with the overall survival rate of cancer patients. This discovery demonstrates that SMO is a potential prognostic marker for cancer. The invention relates to a specific epitope of SMO as an antigen and an antibody or a fragment thereof that recognizes and binds specifically to the epitope. Therefore, the antibody of this invention is expected to be useful as a therapeutic agent for SMO-related cancers. Sang Cheul Oh has 1 patent to his name.

Career Highlights

Sang Cheul Oh is currently associated with Hedgehog, Inc., where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential impact on cancer treatment and patient outcomes.

Collaborations

Sang Cheul Oh collaborates with Dae-Hee Lee, contributing to the innovative research environment at Hedgehog, Inc. Their combined expertise enhances the development of new therapeutic strategies.

Conclusion

Sang Cheul Oh is a dedicated inventor whose work on the SMO protein has the potential to revolutionize cancer treatment. His innovative approach and commitment to research exemplify the importance of scientific advancements in improving patient care.